Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 17, 2017

The Medicines Company

(Exact Name of Registrant as Specified in Charter)

Delaware		000-31191		04-3324394
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

8 Sylvan Way Parsippany, New Jersey		07054
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (973) 290-6000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

On March 17, 2017, The Medicines Company (the “Company”) issued a press release reporting results from the ORION-1 phase 2 study of inclisiran, its PCSK9 synthesis inhibitor. The Company also presented data from the ORION-1 phase 2 study at a Late-Breaking Clinical Trials session at American College of Cardiology’s 66th Annual Scientific Session. A copy of the press release issued by the Company on March 17, 2017, and a copy of the Company’s presentation made on March 17, 2017, are attached hereto as Exhibits 99.1 and 99.2, respectively.

Item 9.01. Exhibits

(d) Exhibits

The following exhibits relating to Item 8.01 shall be deemed to be furnished, and not filed:

99.1 Press release dated March 17, 2017

99.2 Presentation dated March 17, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.